Ma ʻApelila 21, 2026, ua hoʻolaha ke Kikowaena no ka Loiloi Lāʻau Lapaʻau (CDE) o ka National Medical Products Administration ua koho ʻia ʻo HS-20093 no ka inikini (risvutatug rezetecan) ma ke ʻano he moho Breakthrough Therapy no ka mālama ʻana i nā poʻe maʻi me ka maʻi ʻaʻai prostate kūʻē i ka castration holomua i loaʻa mua i ka lāʻau hormonal hou a me ka chemotherapy taxane-based. Lawe mai kēia nūhou i ka manaʻolana hou i nā poʻe maʻi ʻaʻai prostate ma ka honua holoʻokoʻa.
ʻO HS-20093 (HS-20093 / GSK5764227) he B7-H3-targeting antibody-drug conjugate (ADC) i hoʻomohala kūʻokoʻa ʻia e Hansoh. Ma ka 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026), ua hōʻike kūhelu ʻia nā hopena mai kahi hoʻokolohua open-label, multicenter Phase II i kapa ʻia ʻo ARTEMIS-003 (NCT06001255). Ua loiloi ke aʻo ʻana i ka pono a me ka palekana o HS-20093 i nā poʻe maʻi me ka metastatic castration-resistant prostate cancer (mCRPC) i holomua ma hope o hoʻokahi laina mua o ka lāʻau lapaʻau systemic.
Ua hoʻoikaika nā hopena:
- **I nā poʻe maʻi i mālama mua ʻia me nā taxanes:** ʻo ka helu pane i hōʻoia ʻia (cORR) he 38.9%, a ʻo ka helu pane antigen prostate-specific (PSA) (≥50% emi) he 40.7%.
- **I nā poʻe maʻi i mālama ʻole ʻia me nā taxanes:** ʻo ka helu pane i hōʻoia ʻole ʻia (uORR) he 41.7%, a ʻo ka helu pane PSA50 he 23.8%.
Hōʻike kēia mau ʻikepili e hōʻike ana ʻo HS-20093 i ka hana antitumor koʻikoʻi a paʻa hoʻi me ka nānā ʻole i ka chemotherapy taxane ma mua. No nā poʻe maʻi me ka maʻi holomua i kūʻē a hoʻi hou paha ma hope o ke kūlana mālama o kēia manawa (therapy hormonal hou + chemotherapy), ʻo kēia me ke kānalua ʻole he koho hou a waiwai nui hoʻi i ka lāʻau lapaʻau.
**Pehea e hiki ai i nā poʻe maʻi o ka honua ke komo i kēia lāʻau lapaʻau hou loa?**
Inā ʻoe a i ʻole kekahi lālā o ka ʻohana e hakakā nei me ka maʻi ʻaʻai prostate kūʻē i ka castration holomua a ʻaʻole ʻoe i māʻona a ʻaʻole paha e hoʻomanawanui i nā koho lapaʻau e kū nei, hiki iā ʻoe ke kūkākūkā me ka International Department of Beijing South Region Oncology Hospital e loiloi i ke kūpono no ka lāʻau lapaʻau HS-20093. Ma ke ʻano he ʻoihana kūikawā i hiki ke hāʻawi i nā lawelawe lapaʻau honua, ua kūpaʻa ka International Department o ka haukapila i ka hāʻawi ʻana i ka mālama oncology piha i nā poʻe maʻi honua, me ke komo ʻana i nā hoʻokolohua lapaʻau hou a me nā hoʻōla holomua.
**E leka uila mai iā mākou i kēia manawa:**
- **Helu Kelepona:** 400-880-3716
- **WeChat ID:** 17801183037
- **Leka uila:**
① 100085_010@163.com
② myimmnet@163.com
**Nā memo koʻikoʻi:**
- Ma mua o ke kipa ʻana, pono nā mea maʻi o ka honua e hoʻomākaukau i nā unuhi Pelekania/Pākē o nā moʻolelo lapaʻau mua (me nā hōʻike pathology, nā hoʻokolokolo kiʻi, a me nā moʻolelo o ka chemotherapy mua a me ka hormonal therapy) e hoʻomaʻalahi i ka loiloi wikiwiki ʻana o ke kauka.
- Hiki i kā mākou Keʻena Honua ke kōkua me nā leka kono visa lapaʻau, nā hālāwai, a me nā lawelawe unuhi. No nā nīnau kikoʻī, e ʻoluʻolu e hoʻokaʻaʻike mai iā mākou ma o nā ala i luna.
Ka manawa hoʻouna: ʻApelila-28-2026